摘要
目的：评价Ｇｅｍｃｉｔａｂｉｎｅ（中文译名：健择）单药及其与顺氯铵铂联合化疗方案治疗ＩＩ、ＩＶ期非小细胞肺癌（ＮＳＣＬＣ）的临床疗效及其不良反应。材料与方法：１健择单药研究：从１９９７年９月至１９９８年５月入选ＩＩ、ＩＶ期ＮＳＣＬＣ病人２１例，以前未接受过任何化疗、放疗。ＩＩ期病人１１例，ＩＶ期病人１０例。健择１０００ｍｇ／ｍ２，第１，８，１５天各注一次，每２８天为一疗程。２健择与顺氯铵铂联合化疗研究：从１９９７年１０月至１９９８年７月入选ＩＩ、ＩＶ期ＮＳＣＬＣ病人４８例，以前未接受过任何化疗、放疗。ＩＩ期病人１９例，ＩＶ期病人２９例。健择１０００ｍｇ／ｍ２，第１，８，１５天各注一次；顺氯铵铂１００ｍｇ／ｍ２，第一天用，每２８天为一疗程。结果：１健择单药研究：可评价疗效的有１９例，６例获部分缓解（ＰＲ），其中２例（１０５％）经４周以上复查证实。总有效率３１５％［９５％ＣＩ，９４％～４５１５％］。全组均可评价不良反应，少数病人发生轻微胃肠道反应、白细胞下降、血红蛋白下降和血小板下降，只有４８％（各１例）患者发生ＩＩ度的恶心呕吐及白细胞下降，有１例患者发生ＩＩ度感染。全组中位生存期６１３月。２?
Objective: The
aim of the study was to evaluate the clinical efficacy and toxicity of Gemcitabine singledrug and
gemcitabinecisplatin combination in advanced nonsmallcell lung cancer (NSCLC). Methods: 1
gemcitabine singledrug study:Twentyone previously untreated NSCLC patients entered the trial
from September 1997 to May 1998 gemcitabine 1000 mg/m2 was administeredon days 1,8 and
15 in each 28day cycle. 2 GemcitabineCisplatin combination study:Fortyeight previously
untreated NSCLC patients entered the trial from October 1997 to July 1998 Gemcitabine 1000
mg/m2 was administered on days 1,8 and 15 and Cisplatin 100 mg/m2, on day 1 in each 28day
cycle. Results:TBZ1 Gemcitabine singledrug study:Of 19 assessable patients, 6 achieved a
partial response (PR), and among them 2(105%) were confirmed PR. The overall response rate
was 316%(95%confidence interval , 94%to 4515%). 21 patients can be evaluated the toxicity. A
minor proportion of patients experienced mild GI reaction, leukopenia, thrombocytopenia and
decreased hemoglobin levels. Only 48%(1 patient each) of the patients experience grade III
leukopenia and nausea/ vomiting. One patient experienced grade III infection. The median
survival of the whole group was 613 months. 2 Gemcitabinecisplatin combination study:Of 41
assessable patients, 23 achieved a partial response (PR), and among them 18(439%) were
confirmed PR. The overall response rate was 561%(95%confidence interval , 398%to 715%). 48
patients can be evaluated for toxicity. About 1/3 of the patients experienced grade IIIIV
nausea/vomiting and leukopenia and decreased hemoglobin. 1875%(9 patients) experienced
grade III thrombocytopenia. The other toxicity was mild and tolerable. 39 cycles (2437%) of
gemcitabine injections were dosereduced or omitted due to toxicity. The median survival of
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1999年第3期241-245,共5页
Chinese Journal of Cancer
